Overview

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

Status:
Recruiting

Trial end date:
2026-06-29

Target enrollment:

Participant gender:

Summary

A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Osimertinib